<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756964</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB 20081132</org_study_id>
    <nct_id>NCT00756964</nct_id>
  </id_info>
  <brief_title>Lowering Serum Uric Acid to Prevent Acute Kidney Injury</brief_title>
  <acronym>RasbAKI</acronym>
  <official_title>Effect of Rasburicase on Acute Kidney Injury, Kidney Function, the Incidence of Renal Replacement Therapy and All-cause Mortality Following Cardiac Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury is associated with a rise in serum uric acid during cardiovascular
      surgery and can cause poor blood flow to the kidneys making them vulnerable to kidney injury.
      We hypothesize that hyperuricemia, particularly if chronic and marked, is a risk factor for
      acute kidney injury. The preoperative lowering of serum uric acid will reduce the incidence
      of acute kidney injury following cardiovascular surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a prospective, double-blind, placebo-controlled, randomized, clinical
      trial, initiated and implemented conjointly by the Nephrology and Cardiovascular Surgery
      Departments at Shands Hospital at the University of Florida in Gainesville, FL. We propose to
      study whether lowering uric acid provides significant renal and cardiovascular protection in
      subjects undergoing cardiovascular surgery. Up to 30 patients presenting for elective or
      urgent cardiovascular surgery with uric acid level &gt; 6.5 mg/dl and estimated glomerular
      filtration of 30 - 60 ml/min will be included in the study. Patients recruitment will
      continue until up to 30 patients have completed the study, taking into account expected
      patient loss due to withdrawal of consent, incomplete study and other reasons.

      Patients will be randomized to a control group or rasburicase group. Rasburicase or identical
      placebo will be administered to each group after randomization. A selected number of patients
      may undergo additional testing for mechanistic (non-clinical) secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Acute Kidney Injury (AKI).</measure>
    <time_frame>Within 48 hours postoperatively</time_frame>
    <description>Acute kidney injury will be defined as an increase in serum creatinine of 0.3mg/dL from baseline or a 50% increase in serum creatinine from baseline values within 48 hours after surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Rasburicase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving rasburicase to lower serum uric acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will receive a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasburicase</intervention_name>
    <description>Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.</description>
    <arm_group_label>Rasburicase</arm_group_label>
    <other_name>urate oxidase enzyme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive ingredient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older, and

          2. Undergoing elective cardiothoracic surgery(s), alone or in combination with other
             procedures/surgery(s): thoracic aortic aneurysm, cardiac valves, coronary artery
             bypass grafting, abdominal thoracic aneurysm, other CV surgery, and

          3. Preoperative serum uric acid &gt; 6.5 mg/dL, and

          4. Preoperative estimated glomerular filtration rate of &gt;30ml/min/1.73m2 or higher, but
             less than 60ml/min/1.73m2

        Exclusion Criteria:

          1. Prior history of allergy/adverse reaction to Rasburicase

          2. History of any organ transplant

          3. Preoperative intra-aortic balloon pump (IABP)

          4. Known glucose 6-phosphate dehydrogenase (G6PD) deficiency

          5. Current use of natriuretic peptides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Ahsan Ejaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson G, Tabah-Fisch I, Keller B, Beaver TM, Nakagawa T, Johnson RJ. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol. 2007 Jan;2(1):16-21. Epub 2006 Dec 6. Review.</citation>
    <PMID>17699382</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <results_first_submitted>November 23, 2011</results_first_submitted>
  <results_first_submitted_qc>August 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2012</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>hyperuricemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the Cardiovascular Surgery clinics. Written consents were obtained from all patients.</recruitment_details>
      <pre_assignment_details>A large number of patients were screened to achieve the final participant numbers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rasburicase Group</title>
          <description>The drug rasburicase was used in this group.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>This group received an identical placebo of rasburicase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rasburicase Group</title>
          <description>The drug rasburicase was used in this group.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>This group received an identical placebo of rasburicase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Acute Kidney Injury (AKI).</title>
        <description>Acute kidney injury will be defined as an increase in serum creatinine of 0.3mg/dL from baseline or a 50% increase in serum creatinine from baseline values within 48 hours after surgery.</description>
        <time_frame>Within 48 hours postoperatively</time_frame>
        <population>As no similar study has been performed, a power analysis could not be performed. As such, we decided to do a pilot study with 26 subjects and to set criteria to maximize the likelihood of seeing an effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rasburicase Group</title>
            <description>The patients received the drug rasburicase 7.5mg in 50mL of normal saline over 30 minutes period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>The patients which received a placebo identical to rasburicase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Kidney Injury (AKI).</title>
          <description>Acute kidney injury will be defined as an increase in serum creatinine of 0.3mg/dL from baseline or a 50% increase in serum creatinine from baseline values within 48 hours after surgery.</description>
          <population>As no similar study has been performed, a power analysis could not be performed. As such, we decided to do a pilot study with 26 subjects and to set criteria to maximize the likelihood of seeing an effect.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No Adverse Events occurred during the 15 months when data was collected.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rasburicase Group</title>
          <description>The drug rasburicase was used in this group.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>This group received an identical placebo of rasburicase.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of the pilot study is that it was not powered to provide definite answers, an inherent limitation attributed to the absence of similar studies.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>A. Ahsan Ejaz, M.D.</name_or_title>
      <organization>University of Florida</organization>
      <phone>3522735328</phone>
      <email>ejazaa@medicine.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

